Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Azacitidine + Tamibarotene |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Azacitidine | Vidaza | azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg | DNMT inhibitor (Pan) 5 | Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov). |
Tamibarotene | Am 80|SY-1425|TOS-80T|INNO-507 | Tamibarotene (SY-1425) is a synthetic retinoid that activates retinoic acid receptor signaling, which in turn induces differentiation and apoptosis in leukemia cells (PMID: 17925887, PMID: 30093681). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04797780 | Phase III | Azacitidine Azacitidine + Tamibarotene | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | Recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | 0 |
NCT02807558 | Phase II | Azacitidine + Tamibarotene Tamibarotene | A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | FRA | 0 |
NCT06085638 | Phase Ib/II | Azacitidine + Tamibarotene + Venetoclax Azacitidine + Tamibarotene | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | Withdrawn | 0 |